The Triggering Receptor Expressed On Myeloid Cells 1 pipeline drugs market research report outlays comprehensive information on the Triggering Receptor Expressed On Myeloid Cells 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Triggering Receptor Expressed On Myeloid Cells 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Cardiovascular, Gastrointestinal, and Infectious Disease which include the indications Unspecified Immunological Disorders, Acute Inflammation, Myocardial Infarction, Septic Shock, Inflammatory Bowel Disease, Sepsis, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Triggering Receptor Expressed On Myeloid Cells 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Triggering Receptor Expressed On Myeloid Cells 1 pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 2, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Triggering Receptor Expressed On Myeloid Cells 1 overview
Triggering receptor expressed on myeloid cells 1 (TREM1) is a cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses. TREM1 promotes the neutrophil- and macrophage-mediated release of pro-inflammatory cytokines and/or chemokines, as well as their migration, and thereby amplifies inflammatory responses that are triggered by bacterial and fungal infections. It also plays a major role in the pathophysiology of acute and chronic inflammatory diseases of different etiologies including septic shock and atherosclerosis.
For a complete picture of Triggering Receptor Expressed On Myeloid Cells 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
